Goldenburg GJ, et al. Cooperative trial of immunotherapy for nasopharyngeal carcinoma with transfer factor from donors with Epstein-Barr virus antibody activity. Cancer Treat Rep 1985; 69(7-8): 761-7.
A prospective randomized double-blind trial evaluated the effect of immunotherapy with transfer factor as an adjunct to radiotherapy of patients with Stage III nasopharyngeal carcinoma (NPC). One hundred patients were randomized to receive either radiotherapy alone or radiotherapy along with an 18-month course of transfer factor immunotherapy. Patients were followed for at least five years, and no significant difference in disease-free survival or survival was noted between the two groups.
Fujisawa T, et al. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn J Surg 1984; 14(6): 452-8.
One hundred and two patients with primary resected adenocarcinoma of the lung were randomly assigned to a treatment group (transfer factor) and a control group (placebo). The treatment group had significantly higher survival rates than the control group in Stage I cases, while there was no significant difference between groups in patients in stages II, III and IV.
Wagner G, et al. Transfer factor for adjuvant immunotherapy in cervical cancer. Cancer Detect Prev Suppl 1987; 1: 373-6.
In a prospective randomized double-blind study of 60 patients with invasive cervical cancer, one group was treated with transfer factor derived from leukocytes of the patients' husbands, while the control group was treated with placebo. Survival rates among members of the treatment group were significantly higher than those of the control group within the first two years after radical hysterectomy. When the collectives were subdivided, significant differences were found in patients under age 35 and in patients with Stage I disease.
Whyte RI, et al. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg 1992; 53(3): 391-6.
Between 1976 and 1982, 63 patients who underwent pulmonary resection, mediastinal lymph node dissection and, in some cases, mediastinal irradiation, were randomized into two groups. The treatment group received transfer factor at three-month intervals after operation, while the control group received saline solution at identical intervals. The two-year, five-year and 10-year survival rates in patients receiving transfer factor were not statistically significant when compared with the survival rates of the control group, though the differences between the groups were large enough to merit further research.